

Index

Note: Page numbers of article titles are in **boldface** type.

A

- ABCC8 gene, neonatal diabetes and, 519–520
- Acidosis, hypoglycemia and, in premature newborns, 518
- Acquired obesity, 531–533
- ACTH, in premature newborns, adrenal insufficiency and, 514–515
- AD36 virus, obesity associated with, 532
- Adenovirus, obesity associated with, 532
- Adiponectin, metabolic syndrome and, 551, 556–557
- Adipose tissue, calories stored in, 526
- Adipose tissue-derived hormones, metabolic syndrome and, 551–552
- Adrenal disorders, genetics of, 478
- Adrenal insufficiency, genetics of, 478
 - in sick and premature newborns, 514–516
 - bronchopulmonary dysplasia and, 515–516
 - hypotension and, 515
 - pathophysiology of, 514–515
 - temporary, 515
- Adrenoleukodystrophy, genetics of, 478
- Adverse events (AE), with recombinant human insulin-like growth factor-1 therapy, 629–630
 - monitoring for, 631
- Alanine aminotransferase (ALT), fatty liver and, 556
- Albright's hereditary osteodystrophy, obesity associated with, 530
- Alpha melanocyte-stimulating hormone (alpha-MSH), obesity role of, 529–530
- Alström syndrome, obesity associated with, 531–532
- Ambiguous genitalia, therapeutic choices for, molecular genetic studies in, 473
- Amino acids, bone growth and, 568–569
 - in growth hormone products, 588
- AMP/ATP ratio, bone growth and, 572–573
- Anastrozole, for maximizing pubertal growth, chemical structure of, 613–614
 - doses and safety of, 618–619
 - GnRH analogs vs., 614–616
 - gonadotropin-independent precocity and, 617
 - potency of, 617–618
 - studies in boys with growth disorders, 616
- Androgen, in provocative testing, for growth hormone deficiency, 591
- Anorexia nervosa (AN), bone growth and, 570
- Anorexigenic agents, for obesity, 536–537
- Anorexigenic peptides, obesity role of, 527–528
- Anthropometric measurements, in metabolic syndrome definition, 550–552
- Antithyroid drugs, maternal, congenital thyroid disorders and, 501–504
- Appetite regulation, obesity role of, 527–528
 - leptin and, 529

- Appetite suppressants, for obesity, 536–537
- Arginine HCL, for growth hormone deficiency screening, 601–602
- Aromatase inhibitors, for maximizing pubertal growth, 613–619
 - chemical structures of, 613–614
 - doses and safety of, 618–619
 - estradiol assay and, 618
 - gonadotropin-independent precocity and, 617
 - pharmacology of, 613–614
 - physiologic studies of, 614–615
 - potency of, 617–618
 - studies in boys with growth disorders, 614–617
- Assays, estradiol, in estrogen suppression interpretation, for maximizing pubertal growth, 618
 - for insulin-like growth factor deficiency, 625–626, 632
- ATP-sensitive potassium channel, neonatal diabetes and, 519–520
- Autoimmune hyperthyroidism, neonatal, 501–502
- Autoimmune polyglandular syndromes (APS), genetics of, 478
- B**
- Bardet-Biedl syndrome, obesity associated with, 531–532, 537
- Bariatric surgery, for obesity, 538–540
 - forms of, 539
- Behavior, obesity associated with, in children, 525–526, 531, 533
- Behavior modification, for weight loss, in children, 535–536
- Beta adrenergic receptor, obesity and, 531
- β -Blockers, for tachycardia, associated with neonatal hyperthyroidism, 504
- Biochemical profile, of hypoglycemia, in premature newborns, 518
- Biomarkers, of metabolic syndrome, 551
 - inflammation as, 552–554
- Blood pressure, elevated, in metabolic syndrome, 549–552
 - intracranial, with recombinant human insulin-like growth factor-1 therapy, 630
- Body mass index (BMI), in adults, growth hormone deficiency and, 601–602
 - HIV-associated wasting and, 603–604
 - short bowel syndrome and, 604
- in children, growth failure and, 598–599
 - obesity and, 525–528, 531–532
 - evaluation of, 533–534
 - therapy impact on, 535–539
 - therapy indications based on, 533–534
 - metabolic syndrome and, cut-off points for obesity, 534, 551–552
- Bone accretion/bone density, during puberty, aromatase inhibitors for, 618
 - GnRH analogs vs., 616–617
 - GnRH analogs impact on, 613
 - aromatase inhibitors vs., 616–617
- Bone growth, pediatric, cascade of events during, 566
 - epiphyseal. *See Epiphyseal growth plate (EGP).*
 - major periods of, 565
 - nutrition and, **565–586**
 - energy/calories/protein role in, 570–571
 - hormones impact on, 566–569
 - ghrelin, 568

- growth hormone, 566–568
 - insulin, 569
 - insulin-like growth factor-1, 566–568
 - leptin, 568–569
 - molecular mechanisms regulation of, 570–574
 - hypoxia-inducible factor 1, 571–572
 - mammalian target of rapamycin, 572–573
 - microRNAs, 571, 573–574
 - overview of, 570
 - sirtuins, 573
 - specific factors effect on, 574–576
 - iron, 576
 - micronutrients, 575
 - combinations of, 576
 - milk, 576
 - vitamin A, 575
 - vitamin D, 574–575
 - zinc, 575–576
 - summary overview of, 565–567, 576–577
- Brain-derived neurotrophic factor (BDNF), obesity role of, 530
- Breast feeding, obesity and, 533
 - propylthiouracil advantage for, in neonatal hyperthyroidism treatment, 504
- Bronchopulmonary dysplasia (BPD), in premature newborns, adrenal insufficiency and, 515–516

C

- Caffeine, for obesity, 537
- Calcidiol, serum, in premature newborns, 513–514
- Calcitonin, high serum, in premature newborns, 513–514
- Calcium, bone growth and, 575–576
 - homeostasis, vitamin D role in, 574
 - low serum, in premature newborns, 512–514
- Calcium salts, for hypocalcemia, in premature newborns, 514
- Calories, bone growth relationship to, energy, protein and, 570–571
 - sirtuins and, 573
 - restriction of, for obesity, in children, 535
- Cardiovascular disease, in adults, growth hormone deficiency and, 601–602
 - in children, growth hormone therapy associated with, 598
 - metabolic syndrome associated with, 549, 551
 - fatty liver and, 556
- Cartilage growth rate, in children, chronic kidney disease impact on, 592–593
- CATCH-22 syndrome, in premature newborns, hypocalcemia and, 513
- Centers for Disease Control (CDC), on obesity, in children, 551
- Central resistance, in congenital thyroid disorders, 492–493, 495
- Childhood, growth and development as hallmark of, 565–566. See also *Bone growth*.
- Chlorphentermine, for obesity, 537
- Cholesterol metabolism, genetic defects of, 478
- Chromosome mutations, endocrine disorders categories based on, 475
 - in insulin-like growth factor-1 deficiency, 624–625, 627
 - molecular studies of, 475

Chromosome (*continued*)

- neonatal diabetes and, 519–520

- obesity role of, 527–528

- SHOX gene deficiency and, 599

Chronic kidney disease (CKD), in children, growth failure associated with, 591–592

- IGF-1 axis role in, 592–593

- growth hormone therapy for, 593–594

Chronic renal insufficiency, in children, 591–593

- growth hormone therapy for, 593–594

Cloning, positional, in genetic research, 483–484

Combination therapy, for insulin-like growth factor-1 deficiency, 631–632

Congenital growth hormone deficiency, 587–589

Congenital hyperinsulinism, genetics of, 481–482

- in premature newborns, hypoglycemia and, 517

Congenital thyroid disorders, **491–507**

- alternating hypo-, eu-, and hyperthyroidism in neonatal period, 501

- Graves disease and, 501

- maternal antithyroid drugs and, 501–504

- thyrotropin receptor stimulating–blocking antibodies and, 496, 501

- genetic counseling for, 501

- genetics of, 492–496

- iodine deficiency or excess in, 492–493

- maturation and illness role in, 493

- molecular basis of, 492, 494–495

- mother-placenta-fetal unit in, 492, 494, 496

- negative feedback mechanism changes in, 493

- phenotype studies in, 475

- hyperthyroidism as, neonatal, 501–504

- autoimmune hyperthyroidism as, 501–502

- clinical and laboratory data on, 503–504

- diagnosis of, 502

- Graves disease as, 501–502, 504

- non-autoimmune hyperthyroidism as, 504

- permanent, 504

- prognosis of, 504

- transient, 501–502

- treatment of, 502–504

- hypothyroidism as, 496–501

- clinical manifestations of, 497–498

- scoring of with measurements, 498

- diagnostic algorithm for, 498–499

- genetics of, 475, 477

- obesity and, 527–528

- prognosis of, 498, 500–501

- screening for, 496–497

- therapeutic algorithm for, 498–499

- ontogenesis of, 491–492

- screening for, 493, 496–497

Copper, bone growth and, 575–576

Coronary artery disease (CAD), in children, BMI as predictor of, 551–552

- metabolic phenotype and, 552, 554

- Corticotropin-releasing factor (CRH), placental, in premature newborns, 515
- Cortisol, in premature newborns, hyperglycemia and, 519
 - hypoglycemia and, 517–518
 - oxidation of, 514–515
 - disorders of, 515–516
- C-reactive protein (CRP), metabolic syndrome and, 553
- Cushing syndrome, obesity associated with, 528
- Cytokines, metabolic syndrome and, 551–552
 - fatty liver association with, 555–557
 - obesity impact on, 552–554

D

- Databases, online, of genetic information, 472
- Development. See *Growth and development*.
- Diabetes insipidus (DI), genetics of, 478–479
- Diabetes mellitus (DM), maturity-onset, of the young, genetics of, 479
 - metabolic syndrome associated with, 551–552
 - impaired glucose tolerance and, 554–555
 - neonatal, in premature newborns, 519–520
 - small for gestational age associated with, 598
 - type 1, bone growth and, 569
 - type 2. See *Type 2 diabetes mellitus*.
- Dialysis, for chronic kidney disease, in children, as growth factor, 593
- Dietary approach, to obesity, in children, 534–535
- Diethylpropion, for obesity, 537
- DiGeorge syndrome, in premature newborns, hypocalcemia and, 513–514
- DNA microarray, in genetic research, 484–485
- DNA sequencing, in genetic research, 482–483
 - “junk,” 573
- DNA technology, historical background on, 482
 - new, applications of, 482–485
 - recombinant, implication of, 471–472

E

- Endocrine disorders, in newborns, **509–524**
 - adrenal insufficiency as, 514–516
 - hyperglycemia as, 518–520
 - hypocalcemia as, 512–514
 - hypoglycemia as, 516–518
 - of thyroid, 509–512
 - summary overview of, 509
- pediatric. See also *specific disorder*.
 - ethnicity variations of, metabolic syndrome and, 550, 556
 - obesity and, 525, 531, 533
 - genetic classification of, 474. See also *Genetic disorders*.
 - hormone level classification of, 475
- Energy, bone growth relationship to, calories, protein and, 570–571
 - dietary restriction of, for obesity, in children, 535
 - expenditure of, in premature newborns, hypoglycemia and, 517
 - obesity and, 526

- Environment, obesity associated with, 525–526, 531, 533
- Ephedrine, for obesity, 537
- Epigenetic mechanism, in bone growth regulation, 573–574
in obesity, 533
- Epiphyseal growth plate (EGP), fusion of, GnRH analogs impact on, during puberty, 613–614
growth hormone role in, 625
linear growth and, malnutrition effect on, 570–571
nutritional factors of, 566–567, 569, 573
organization of, 566
- Estradiol assay, in estrogen suppression interpretation, for maximizing pubertal growth, 618
- Estrogen, in provocative testing, for growth hormone deficiency, 591
- Estrogen receptor, genetic defects of, 477–478
- Estrogen receptor blockers, for precocious puberty, 617
- Estrogen suppression, for breast cancer, 613, 617
for maximizing pubertal growth, in boys with short stature, aromatase inhibitors for, 613–614
physiologic studies of, 614
precocious puberty and, 617
study results review, 614–617
- Ethnicity, in pediatric endocrinology disorders, metabolic syndrome and, 550, 556
obesity and, 525, 531, 533
- Eukaryotic initiation factor 4E (eIF4E), bone growth and, 572
- Euthyroidism, congenital, alternating hypo- and hyperthyroidism with, in neonatal period, 496, 501
- Exemestane, for maximizing pubertal growth, chemical structure of, 613–614
doses and safety of, 618–619
potency of, 617–618
- Exercise, for weight loss, in children, 535
- Extracellular matrix (ECM), of epiphyseal growth plate, 566, 574

F

- Familial glucocorticoid deficiency (FGD), 478
- Familial male precocious puberty, genetics of, 480–481
- Fasting glucose, impaired, in type 2 diabetes, 554–555
fatty liver and, 556
- Fat accumulation/distribution, hepatic, in metabolic syndrome, 555–557
phenotype perspectives of, 552
visceral, in metabolic syndrome, 549–551, 556–557
- Fat mass and obesity associated (*FTO*) gene locus, adiposity expression and, 530–531
- Fatty acids, free, accumulation of, insulin resistance associated with, 549–550, 556
metabolic syndrome and, 551, 554
oxidation of, hypoglycemia and, in premature newborns, 518
- Fatty liver, metabolic syndrome associated with, 555–557
phenotype perspectives of, 552
- Feedings/formulas, for premature newborns, hyperglycemia related to, 519
in hypocalcemia management, 514
- Fenfluramine, for obesity, 537
- Fetal thyroid gland, ontogenesis of, 491–492

Fluorescent in situ hybridization (FISH), 482
Folic acid, bone growth and, 576
Food and Drug Administration (FDA), U.S., appetite suppressants approvals, 536–537
 growth hormone product approvals, 588, 596, 598, 613, 631
Forkhead transcription factor (FoxO1), in metabolic syndrome, 552
Four-step approach, to obesity, in children, 536–540
Free fatty acid (FAA), accumulation of, insulin resistance associated with, 549–550, 556
 metabolic syndrome and, 551, 554
FTO gene, adiposity expression and, 530–531
Functional genomics, 484–485

G

G protein, molecular studies of, 475, 481
G protein-coupled receptors, molecular studies of, 475
Gain of function, endocrine disorders categories based on, 475
 genetic mechanisms in, 480–482
Gastric banding, for obesity, laparoscopic adjustable, 539
 vertical, 539
Gastrointestinal lipase inhibitors, for obesity, 537–538
Gastroplasty, vertical banded, for obesity, 539
Gene alterations/mutations. *See also Chromosome mutations.*
 traditional classification of, 473–475
Gene encoding, of thyroid tumors, 473
Gene expression, obesity associated with, 533
 polymorphisms and, 473
 serial analysis of, 484–485
Gene products, polymorphisms and, 473
Gene sequencing, 471–472
Genentech, 588, 631
Genetic counseling, for congenital thyroid disorders, 501
Genetic disorders, hypersecretory, 480–482
 congenital hyperinsulinism as, 481–482
 gigantism as, 480
 hyperthyroidism as, 481
 precocious puberty as, 480–481
 hypofunctional, 475–480
 hypoparathyroidism as, 479–480
 maturity-onset diabetes of the young as, 479
 of adrenals, 478
 of neurohypophysis, 478–479
 of reproductive axis, 477–478
 of thyroid, 477
 short stature as, 476–477
 molecular studies of, advances in, 471–473, 475
 principal pediatric, 474
Genetics, in pediatric endocrinology, **471–490**
 drug applications of, 473
 Internet information exchange on, 472
 of congenital thyroid disorders, 492–496
 iodine deficiency or excess in, 492–493

Genetics (*continued*)

- maturation and illness role in, 493
 - molecular basis of, 492, 494–495
 - mother-placenta-fetal unit in, 492, 494, 496
 - negative feedback mechanism changes in, 493
 - of gain of function disorders, 480–482
 - of growth hormone deficiency, 589, 627
 - of growth hormone products, 588
 - of growth hormone receptor insensitivity, 624–625, 627
 - of insulin-like growth factor-1 deficiency, 624–625, 627
 - of loss of function disorders, 475–480
 - of metabolic syndrome, 552, 558
 - of neonatal diabetes, 519–520
 - of Noonan syndrome, 600–601
 - of obesity, 526–527, 529
 - allelic variations affecting energy balance, 530–531
 - of short stature, 599
 - of testotoxicosis, 617
 - of type 2 diabetes, 554–555, 558
 - pathology applications of, 473–475
 - classifications based on, 475–482. See also *Genetic disorders*.
 - polymorphisms and, 473
 - research advances in, 471–472
 - summary overview of, 485
 - techniques for, 482–485
 - DNA microarray as, 484–485
 - DNA sequencing as, 482–483
 - functional genomics as, 484–485
 - historical background on, 482
 - linkage analysis as, 483–484
 - polymerase chain reaction as, 482
 - positional cloning as, 483–484
 - therapeutic implications of, 472–473
- Genomic Human Project, 471–472, 573
- Genomics, functional, 484–485
 - in pediatric endocrinology, **471–490**. See also *Genetics*.
- Ghrelin, bone growth role of, 568
- Gigantism, genetics of, 480
- Glucocorticoid deficiency, genetics of, 478
- Glucokinase (GCK), bone growth and, 569
 - deficiency of, neonatal diabetes related to, 519–520
- Gluconeogenesis, in premature newborns, 516–517
 - disorders of, 518–519
- Glucose, plasma, in metabolic syndrome definition, 549–551
 - in premature newborns, hyperglycemia and, 518
 - hypoglycemia and, 516, 518
- Glucose homeostasis, neonatal, goal of, 516
- Glucose infusions, for premature newborns, hyperglycemia and, 519
- Glucose tolerance, impaired, metabolic syndrome associated with, 549–551
 - fatty liver and, 556
 - type 2 diabetes and, 554–555

- Glucose tolerance test (GTT), oral, for type 2 diabetes, 554
 - fatty liver and, 556
- Glycemic response, hypoglycemia and, in premature newborns, 517
- Glycogen stores, in premature newborns, 516–517
 - disorders of, 518
- Glycogenolysis, in premature newborns, 516–517
 - disorders of, 518
- GnRH analogs, for maximizing pubertal growth, 613–614
 - anastrozole treatment vs., 614–615
- Gonadotropin-independent precocious puberty (GIP), estrogen blockers for, 617
- Gonadotropin-releasing hormone (GnRH), genetic defects of, 477
- Graves disease (GD), genetics of, 481
 - maternal, central congenital hypothyroidism and, 501
 - neonatal hyperthyroidism and, 501–502, 504
 - treatment during pregnancy, 502
- Growth and development, as childhood hallmark, 565–566
 - linear/longitudinal. *See Bone growth.*
 - psycho-neuro-intellectual, congenital thyroidism associated with, 496
 - thyroxine replacement and, 498, 500–501
- Growth failure/retardation, in children, chronic kidney disease associated with, 591–593
 - Prader-Willi syndrome and, 596–597
 - pubertal growth maximizing strategies for, **613–624**. *See also Pubertal growth.*
 - Turner syndrome and, 594–595
- intrauterine, in premature newborns, hypoglycemia risk and, 516–517
- Growth hormone (GH), bone growth role of, 566–568
 - deficiency of. *See Growth hormone deficiency (GHD).*
 - elevation of, genetics of, 480
 - in premature newborns, hyperglycemia and, 519
 - expansion of availability, **587–611**
 - approved brands of, 588–590
 - for adult therapy, 601–605
 - for children's therapy, 589–601
 - summary overview of, 587–588, 605
 - high-dose, for maximizing pubertal growth, 613–614
 - secretion pattern of, 589
 - therapy indications for adults, growth hormone deficiency as, 601–602
 - HIV-associated wasting as, 602–603
 - short bowel syndrome as, 603–605
 - therapy indications for children, chronic renal insufficiency as, 591–594
 - growth hormone deficiency as, 589–591
 - idiopathic short stature as, 598–599
 - Noonan syndrome as, 600–601
 - Prader-Willi syndrome as, 596–598
 - short stature homeobox-containing gene deficiency as, 599
 - small for gestational age as, 598
 - Turner syndrome as, 594–596
- Growth hormone deficiency (GHD), acquired, 589, 601
 - congenital, 587–589
 - etiologies of, 589, 601
 - genetics of, 476–477

Growth (*continued*)

- in adolescents, short stature associated with, 613–615
- in adults, characteristics of, 601–602
 - diagnosis of, 601–602
 - etiologies of, 601
 - therapy for, 602
- in children, etiologies of, 589, 592–594
 - obesity associated with, 528
 - screening for, 589–591
 - short stature and, 624, 627
 - therapy for, 591, 593–594, 596
 - failures of, 631–632
- in premature newborns, hypoglycemia and, 517–518
- Laron syndrome vs., 625, 629
- Growth hormone (GH)/insulin-like growth factor (IGF-1) axis, in children, chronic kidney disease and, 592–593
 - Noonan syndrome and, 600–601
 - primary deficiency pathophysiology of, 624–625, 627
 - combination treatment for, 631–632
 - schematic of, 626
- Growth hormone (GH) receptor, mutations of, in insulin-like growth factor-1 deficiency, 624–625, 627
- Growth hormone (GH) stimulation tests, for growth hormone deficiency, in adults, 601–602
 - for insulin-like growth factor deficiency, 625
- Growth plate. See *Epiphyseal growth plate (EGP)*.

H

- Height, growth hormone deficiency impact on. See *Short stature*.
- High-density lipoprotein (HDL), in metabolic syndrome, 550–551, 556
- High-dose growth hormone, for maximizing pubertal growth, 613–614
- Highly active antiretroviral treatment (HAART), HIV-associated wasting and, 602–603
- Histone deacetylases (HDAC), class III, bone growth regulation by, 573
- HIV-associated wasting, in adults, causes of, 602–603
 - description of, 602
 - growth hormone therapy for, 603–604
- HLA genes, linkage analysis of, 484
- Hormone receptors, molecular studies of, 472–473, 475
- Hormone replacement therapy, molecular studies of, 473
 - recombinant human insulin-like growth factor-1 as, adverse events with, 629–630
 - monitoring for, 631
- Hormones. See also *specific hormone*.
 - bone growth role of, 566–569
 - ghrelin, 568
 - growth hormone, 566–568
 - insulin, 569
 - insulin-like growth factor-1, 566–568
 - leptin, 568–569
 - levels of, endocrine disorders categories based on, 475
- Human immunoglobulin therapy, maternal, for neonatal hyperthyroidism, 502–504

- Hydrocortisone, for adrenal insufficiency, in premature newborns, 515–516
- Hyperglycemia, in sick and premature newborns, 518–520
 - complications of, 519
 - definition of, 518–519
 - etiology of, 519
 - management of, 519
- Hyperinsulinemia, metabolic syndrome and, 552
- Hyperinsulinism, congenital, genetics of, 481–482
 - in premature newborns, hypoglycemia and, 517–518
- Hyperinsulinism/hyperammonemia syndrome, in premature newborns, hypoglycemia and, 517
- Hypersecretory endocrine disorders, 475
 - genetics of, 480–482
 - congenital hyperinsulinism as, 481–482
 - gigantism as, 480
 - hyperthyroidism as, 481
 - precocious puberty as, 480–481
- Hypertension, in metabolic syndrome, 549–552
 - intracranial, with recombinant human insulin-like growth factor-1 therapy, 630
- Hyperthyroidism, genetics of, 481
 - neonatal, 501–504
 - alternating hypo-, and euthyroidism with, 496, 501
 - autoimmune hyperthyroidism as, 501–502
 - clinical and laboratory data on, 503–504
 - diagnosis of, 502
 - Graves disease as, 501–502, 504
 - non-autoimmune hyperthyroidism as, 504
 - permanent hyperthyroidism as, 504
 - prognosis of, 504
 - transient hyperthyroidism as, 501–502
 - treatment of, 502–504
- Hypocalcemia, in sick and premature newborns, 512–514
 - early neonatal, 512–513
 - evaluation of, 514
 - late neonatal, 513–514
 - management of, 514
 - overview of, 512
- Hypofunctional genetic disorders, 475–480
 - hypoparathyroidism as, 479–480
 - maturity-onset diabetes of the young as, 479
 - of adrenals, 478
 - of neurohypophysis, 478–479
 - of reproductive axis, 477–478
 - of thyroid, 477
 - short stature as, 476–477
- Hypoglycemia, in sick and premature newborns, 516–518
 - acidosis with, 518
 - biochemical profile of, 518
 - counter-regulatory hormones and, 517–518
 - definition of, 516
 - diagnostic algorithms for, 518

- Hypoglycemia (*continued*)
 energy expenditure and, 517
 glucose homeostasis vs., 516–517
 hepatomegaly and, 518
 hyperinsulinism and, 517
 metabolic disorders and, 518
 miscellaneous etiologies of, 517
 physical examination for, 518
 with recombinant human insulin-like growth factor-1 therapy, 630
- Hypogonadism, genetics of, 477–478
- Hypoparathyroidism, genetics of, 479–480
 in premature newborns, 512–514
- Hyposecretory endocrine disorders, 475–480
 genetics of. *See Hypofunctional genetic disorders.*
- Hypotension, in premature newborns, adrenal insufficiency and, 515
- Hypothalamic obesity, in children, 528–529
 simplified model of, 527–528
- Hypothalamic thyrotrophin-releasing hormone (TRH), in premature newborns, 510
- Hypothalamic-pituitary-adrenal (HPA) axis, development of, in premature newborns, 514–515
 in congenital thyroid disorders, fetal thyroid gland ontogenesis and, 491–492
 mother-placenta-fetal unit and, 492, 494–496
- Hypothalamic-pituitary-gonadal axis, genetic defects of, 477–478
- Hypothyroidism, congenital, 496–501
 alternating eu-, and hyperthyroidism with, in neonatal period, 496, 501
 clinical manifestations of, 497–498
 scoring of with measurements, 498
 diagnostic algorithm for, 498–499
 genetics of, 475
 prognosis of, 498, 500–501
 screening for, 496–497
 therapeutic algorithm for, 498–499
 obesity associated with, 527–528
 primary, in premature newborns, 512
- Hypothyroxinemia, transient, in premature newborns, 510–511
- Hypoxia-inducible factor (HIF) 1, bone growth regulation by, 571–572

I

- IGF-1* gene mutations, in insulin-like growth factor-1 deficiency, 624–625, 627
- Illness role, in congenital thyroid disorders, 493
- Immunoglobulin therapy, human maternal, for neonatal hyperthyroidism, 502–504
- Impaired fasting glucose (IFG), in type 2 diabetes, 554–555
 fatty liver and, 556
- Impaired glucose tolerance (IGT), metabolic syndrome associated with, 549–551
 fatty liver and, 556
 type 2 diabetes and, 554–555
- Inborn error of thyroid hormonogenesis, 492, 494
- Inclusion body technology, 588
- Inflammation, in metabolic syndrome, biomarkers of, 552–554
 fatty liver and, 555–556

- Insulin, bone growth role of, 569, 574
 - dysregulation of, in premature newborns, hypoglycemia and, 517
 - secretion of, obesity and, 528, 538
- Insulin resistance, bone growth and, 569
 - in children, growth hormone therapy associated with, 598
 - obesity and, 538
 - in premature newborns, hyperglycemia and, 519
 - metabolic syndrome associated with, 549–550
 - fatty liver and, 555–557
 - genetic studies of, 558
 - impact on biomarkers, 552–554
 - small for gestational age associated with, 598
- Insulin therapy, for hyperglycemia, in premature newborns, 519–520
 - for obesity, 538
- Insulin tolerance test (ITT), for growth hormone deficiency screening, in adults, 601–602
 - in children, 589–590
- Insulin-like growth factor-1 (IGF-1), bone growth role of, 566–568
 - milk and, 576
 - zinc and, 575
 - deficiency of. *See Insulin-like growth factor-1 (IGF-1) deficiency.*
 - in adolescents, short stature and, 613, 618
 - in adults, growth hormone deficiency and, 601–602
 - HIV-associated wasting and, 603
 - in children, chronic kidney disease and, 592–593
 - Noonan syndrome and, 600–601
 - obesity and, 528, 538
 - short stature and, 624, 627
 - recombinant human, **625–638**. *See also Recombinant human insulin-like growth factor-1 (rhIGF-1).*
- Insulin-like growth factor-1 (IGF-1) deficiency, recombinant human growth hormone for, 631
 - failures of, 631–632
 - recombinant human insulin-like growth factor-1 for, 627–632
 - combination therapy, 632
 - diagnosis of, 624
 - dosing of, 630
 - expanded concept of primary, 631
 - failures of, 631–632
 - future of, 631–632
 - idiopathic short stature vs., 631
 - in primetime, 632
 - laboratory testing impact and, 624–627
 - Laron syndrome indication, 627–628
 - molecular etiologies of, 624–626, 632
 - monitoring of, 631
 - pathophysiology of, 625–626
 - prevalence of, 624–625
 - primary continuum of, 627
 - primary indication, 628–629
 - safety of, 629–630
 - severe primary indication, 628
 - summary overview of, 627, 632

- Insulinoma, obesity associated with, 528
- Interleukin (IL)-6, metabolic syndrome and, 553–554
- International Diabetes Federation, metabolic syndrome definition of, in children, 550–551
- Internet resources, on genetic information, 472
- Intestinal disease, in adults, causes of, 604
 - growth hormone therapy for, 604–605
 - animal data on, 603–604
- Intracranial hypertension, with recombinant human insulin-like growth factor-1 therapy, 630
- Intrauterine growth retardation (IUGR), in premature newborns, hypoglycemia risk and, 516–517
- Iodine, bone growth and, 575
 - deficiency or excess of, in congenital thyroid disorders, 492–493
- Iodine therapy, high-dose maternal, for neonatal hyperthyroidism, 502–503
- Iron, bone growth and, 575–576

J

- JAK2 pathway, in chronic renal insufficiency, 593
 - in insulin-like growth factor-1 deficiency, 624, 626

K

- Ketoacidosis, in premature newborns, hypoglycemia and, 518
- Kidney disease. See *Chronic kidney disease (CKD)*.

L

- Laboratory tests/testing, for neonatal hyperthyroidism, 503–504
 - impact on insulin-like growth factor-1 deficiency prevalence, 624–627
- Lactate, high serum, in premature newborns, hypoglycemia and, 518
- Lactation, propylthiouracil advantage for, in neonatal hyperthyroidism treatment, 504
- Laparoscopic adjustable gastric banding (LAGB), for obesity, 539
- Laron syndrome, growth hormone deficiency vs., 625, 629
 - recombinant human insulin-like growth factor-1 for, 627–628
- Leptin, appetite regulation role of, 529
 - bone growth role of, 568–569
 - for obesity, 538
 - metabolic syndrome and, 551
- Leptin receptor, mutations of, obesity associated with, 529
- Leptin signaling pathway, mutations of, obesity associated with, 527, 529–530
- Letrozole, for maximizing pubertal growth, chemical structure of, 613–614
 - doses and safety of, 618
 - potency of, 617–618
 - studies in boys with growth disorders, 614–617
- Linear growth. See *Bone growth*.
- Linkage analysis, in genetic research, 483–484
- Lipid disorders, in adults, growth hormone deficiency and, 601–602
 - in children, growth hormone therapy associated with, 598
 - metabolic syndrome associated with, 549–552, 554, 557
 - insulin resistance and, 555–557
 - small for gestational age associated with, 598

- Lipid infusions, for premature newborns, hyperglycemia related to, 519
- Lipid kinases, p13K, bone growth and, 572–573
- Longitudinal growth. *See Bone growth.*
- Loss of function, endocrine disorders categories based on, 475
 - genetic mechanisms in, 475–480
- Low birth weight (LBW) infants, hypocalcemia in, 513
 - thyroid disorders in, 510, 512
- Luteinizing hormone (LH) receptor gene, in hypogonadism, 477
 - in testotoxicosis, 617

M

- Magnesium, bone growth and, 575
 - serum, in premature newborns, hypocalcemia and, 513–514
- Malnutrition, protein-energy, bone growth and, 570–571
- Mammalian target of rapamycin (mTOR), bone growth regulation by, 572–573
- Marasmus, bone growth and, 570
- Maternal antithyroid drugs, congenital thyroid disorders and, 501–504
- Maternal Graves disease, central congenital hypothyroidism and, 501
 - neonatal hyperthyroidism and, 501–502, 504
 - treatment during pregnancy, 502
- Maternal nutrition, pediatric obesity associated with, 533
- Maturation role, in congenital thyroid disorders, 493
- Maturity-onset diabetes of the young (MODY), genetics of, 479
- Mazindol, for obesity, 537
- McCune Albright syndrome (MAS), genetics of, 480–481
 - precocious puberty related to, 617, 619
- Medications, for obesity, in children, 536–538
 - obesity associated with, 531–532
- Mediterranean diet, for obesity, in children, 534–535
- Melanocortin receptors, obesity role of, 530
- Melanocortins, obesity role of, 527–528
- Melanocyte-stimulating hormone (MSH), alpha, obesity role of, 529–530
- MEN1 gene, linkage analysis of, 483–484
- Mental development, congenital thyroidism associated with, 496
 - thyroxine replacement and, 498, 500–501
- Metabolic disorders, in metabolic syndrome definition, 549–551
 - in premature newborns, hypoglycemia and, 518
- Metabolic phenotype, of metabolic syndrome, in children, 552–554
- Metabolic syndrome (MS), in pediatrics, **549–563**
 - conclusions about, 557
 - definition of, 550–551
 - fatty liver associated with, 555–557
 - future perspectives for, 558
 - identification of, 551–552
 - impaired glucose tolerance and, 549–551
 - type 2 diabetes with, 554–555
 - obesity and, BMI cut-off points for, 534, 551–552
 - pathogenesis of, 549–550
 - phenotype of, 552–554
- Metformin, for obesity, 538

- Methimazole, high-dose maternal, for neonatal hyperthyroidism, 502
- Microarray technology, DNA, 484–485
- Micronutrients, bone growth and, 575–576
 - combinations of, 576
- MicroRNAs (miRNAs), bone growth regulation by, 571, 573–574
- Milk, bone growth role of, 576
- MMPs, bone growth and, 575–576
- Molecular biology, genetic defect applications of, 473
 - research advances in, 471–472
 - therapeutic implications of, 472–473
- Molecular etiologies, of congenital thyroid disorders, 492, 494–495
 - of insulin-like growth factor-1 deficiency, 624–625, 627, 632
- Molecular mechanisms, of bone growth regulation, 570–574
 - hypoxia-inducible factor 1, 571–572
 - mammalian target of rapamycin, 572–573
 - microRNAs, 571, 573–574
 - overview of, 570
 - sirtuins, 573
- Mother-placenta-fetal unit, in congenital thyroid disorders, 492, 494, 496
- mRNA-375, bone growth and, 574

N

- National Cooperative Growth Study (NCGS), 596, 625, 631
- National Pituitary Agency (NPA), 587–588
- Negative feedback mechanism, in congenital thyroid disorders, 493
- Neonatal diabetes, transient vs. permanent, 519–520
- Neonatal hyperthyroidism, 501–504
 - alternating hypo-, and euthyroidism with, 496, 501
 - autoimmune, 501–502
 - clinical and laboratory data on, 503–504
 - diagnosis of, 502
 - Graves disease as, 501–502, 504
 - non-autoimmune, 504
 - permanent, 504
 - prognosis of, 504
 - transient, 501–502
 - treatment of, 502–504
- Neonatal hypocalcemia, in sick and premature newborns, early, 512–513
 - late, 513–514
- Neonatal nutrition, obesity and, 533
- Neurohypophysis disorders, genetics of, 478–479
- Neuropeptides, obesity role of, 527–528
- Neurotransmitter regulators, for obesity, 536–537
- Newborns, premature. *See also Premature newborns.*
 - endocrine disorders in, **509–524**
 - sick, **509–524**
 - adrenal insufficiency in, 514–516
 - endocrine disorders summary of, 509
 - hyperglycemia in, 518–520
 - hypocalcemia in, 512–514

- hypoglycemia in, 516–518
 - thyroid disorders in, 509–512
- Nicotinamide adenine dinucleotide (NAD), class III, bone growth regulation by, 573
- Nonalcoholic fatty liver disease (NAFLD), insulin resistance precipitating, 555
- metabolic syndrome associated with, 555–557
- Non-autoimmune hyperthyroidism, neonatal, 504
- Nonthyroidal illness, in premature newborns, thyroid disorders related to, 511–512
- Noonan syndrome (NS), in children, characteristics of, 600–601
- growth hormone therapy for, 601
- Nutrition, in pediatrics, bone growth and, **565–586**
- energy/calories/protein role in, 570–571
 - hormones impact on, 566–569
 - ghrelin, 568
 - growth hormone, 566–568
 - insulin, 569
 - insulin-like growth factor-1, 566–568
 - leptin, 568–569
 - molecular mechanisms regulation of, 570–574
 - hypoxia-inducible factor 1, 571–572
 - mammalian target of rapamycin, 572–573
 - microRNAs, 571, 573–574
 - overview of, 570
 - sirtuins, 573
 - specific factors effect on, 574–576
 - iron, 576
 - micronutrients, 575
 - combinations of, 576
 - milk, 576
 - vitamin A, 575
 - vitamin D, 574–575
 - zinc, 575–576
 - summary overview of, 565–567, 576–577
 - neonatal, obesity and, 533
 - maternal, pediatric obesity associated with, 533

O

- Obesity, pediatric, **525–548**
- body mass index in, 525–528, 531–532
 - evaluation of, 533–534
 - therapy based on, 533–534
 - therapy impact on, 536–539
- etiologies of, 526–533
- acquired, 531–533
 - allelic variations affecting energy balance as, 530–531
 - classical endocrine disorders as, 527–528
 - Cushing syndrome as, 528
 - genetics in, 526–527, 529–531
 - growth hormone deficiency as, 528
 - hypothyroidism as, 527–528

Obesity (*continued*)

- insulinoma as, 528
- leptin signaling pathway mutations as, 527, 529–530
- social-ecological model of, 525–526, 531, 533
- structural hypothalamus disorders as, 528–529
- syndromic, 531–532
- evaluation algorithm for, 533–534
- metabolic syndrome associated with, 549–551, 557
 - BMI cut-off points for, 534, 551–552
 - fatty liver and, 556
 - genetic studies of, 558
 - impact on biomarkers, 552–554
 - type 2 diabetes risk and, 554–555
- prevalence of, 525
- summary overview of, 525–526, 540
- therapy for, 533–540
 - bariatric surgery as, 538–540
 - behavior modification as, 535–536
 - combined approaches as, 536
 - diets as, 534–535
 - exercise as, 535
 - indications for, 533–534
 - medications as, 536–538
- Octreotide, for obesity, 538
- Online Mendelian Inheritance in Man (OMIM)*, 472
- Ontogenesis, of thyroid function, 491–492
- Oral glucose tolerance test (OGTT), for type 2 diabetes, 554
 - fatty liver and, 556
- Orlistat, for obesity, 537–538
- Ovarian cysts, aromatase blockade and, 619
- Overweight. *See Obesity.*
- Oxidative stress, fatty liver and, 555–556

P

- P13K lipid kinases, bone growth and, 572–573
- Parathyroid hormone (PTH) disorders, genetics of, 479–480
 - in premature newborns, 512–514
- Parenteral nutrition (PN), for short bowel syndrome, growth hormone therapy impact on need for, 604–605
- Peptide hormone receptors, molecular studies of, 475
- Perilipin, obesity and, 531
- Perinatal endocrinology, common disorders in, **509–524**
 - adrenal insufficiency as, 514–516
 - hyperglycemia as, 518–520
 - hypocalcemia as, 512–514
 - hypoglycemia as, 516–518
 - of thyroid, 509–512
 - summary overview of, 509
- Peroxisome proliferator-activated receptors (PPAR- γ), obesity and, 531
- Pharmacogenetics, 473
- Pharmacogenomics, 473

- Pharmacologic stimuli, for growth hormone deficiency screening, in children, 589–591
- Phenotype, alterations of, molecular studies of, 475
 - metabolic, of children, with metabolic syndrome, 552–554
- Phentermine, for obesity, 537
- Phosphorous, bone growth and, 575
- Polymerase chain reaction (PCR), in genetic research, 482
- Polymorphisms, genetic consequences of, 473, 483
 - obesity and, 531
 - single-nucleotide, bone growth and, 575
 - obesity and, 530–531
- Positional cloning, in genetic research, 483–484
- Postreceptor signaling mechanisms, molecular studies of, 472
- Potassium, bone growth and, 576
- Potassium channel, ATP-sensitive, neonatal diabetes and, 519–520
- Prader-Willi syndrome (PWS), in children, characteristics of, 596–597
 - growth hormone therapy for, 597–598
 - obesity associated with, 531–532
 - unexpected death from, 597
- Precocious puberty, genetics of, 480–481
 - GnRH analogs impact on, 613–614
 - gonadotropin-independent, 617
- Premature newborns, endocrine disorders in, **509–524**
 - adrenal insufficiency as, 514–516
 - hyperglycemia as, 518–520
 - hypocalcemia as, 512–514
 - hypoglycemia as, 516–518
 - of thyroid, 509–512
 - summary overview of, 509
- Primary hypothyroidism, in premature newborns, 512
- Prohormone convertase 1 (PC1), obesity role of, 529
- Proinflammatory state, metabolic syndrome and, 552–554
- Pro-opiomelanocortin (POMC), obesity role of, 529
 - processing of, mutations in, 529
- Propylthiouracil, high-dose maternal, for neonatal hyperthyroidism, 502, 504
- Protein, biosynthesis of, in thyroid function ontogenesis, 492
 - bone growth relationship to, energy, calories and, 570–571
 - encoding of, bone growth and, 573–574
- Protein secretion technology, 588
- Protein-energy malnutrition (PEM), bone growth and, 570–571
- Proteomics, therapeutic implications of, 472–473
- Provocative testing, for growth hormone deficiency, in children, 589–591, 625
- Pseudohypoparathyroidism (PHP), genetics of, 479–480
 - obesity associated with, 530
- Pseudopseudohypoparathyroidism (PPHP), obesity associated with, 530
- Psycho-neuro-intellectual development, congenital thyroidism associated with, 496
 - thyroxine replacement and, 498, 500–501
- PTPN11 gene, in Noonan syndrome, 600–601
- Pubertal growth, maximizing in short stature, **613–624**
 - aromatase inhibitors as, 613–619
 - chemical structure of, 613–614
 - doses and safety of, 618–619

Pubertal (*continued*)

- estradiol assay and, 618
 - gonadotropin-independent precocity and, 617
 - pharmacology of, 613–614
 - physiologic studies of, 614–615
 - potency of, 617–618
 - studies in boys with growth disorders, 614–617
 - GnRH analogs as, 613–614
 - high-dose growth hormone as, 613–614
 - summary overview of, 613, 620
 - of bone, 565
- Puberty, precocious. *See Precocious puberty.*

R

- Reactive oxygen species, fatty liver and, 555–556
- Recombinant DNA technology, implication of, 471–472
- Recombinant DNA-derived human GH, 588
- Recombinant human growth hormone (rhGH), 588
 - for growth hormone deficiency. *See Growth hormone deficiency (GHD).*
 - for insulin-like growth factor-1 deficiency, 631
 - failures of, 631–632
- Recombinant human insulin-like growth factor-1 (rhIGF-1), **625–638**
 - for insulin-like growth factor-1 deficiency, 627–632
 - combination therapy, 632
 - dosing of, 630
 - expanded concept of primary, 631
 - failures of, 631–632
 - future of, 631–632
 - idiopathic short stature vs., 631
 - in primetime, 632
 - Laron syndrome indication, 625, 629–630
 - monitoring of, 631
 - pathophysiologic background of, 625–629
 - primary indication, 628–629
 - safety of, 629–630
 - severe primary indication, 628
 - summary overview of, 627, 632
- Renal insufficiency, chronic, in children, 591–593
 - growth hormone therapy for, 591–594
- Renal transplantation, for chronic kidney disease, in children, growth hormone therapy and, 594
- Reproductive axis, genetics of, 477–478
- Reproductive fitness, energy hypothesis of, 526
- Research, clinical, on genetic and molecular biology, 471–472
- Restriction fragment length polymorphism (RFLP), 482
- Retinoic acid, bone growth and, 575
- Ribosomal protein S6 kinase (S6K), bone growth and, 572
- Rickets, short stature vs., 575
- Rimonabant, for obesity, 537
- RNA-induced silencing complex (RISC), bone growth and, 573–574

RNAse-III enzymes, bone growth and, 573–574
Roux-en-Y gastric bypass, for obesity, 539

S

- Screening programs, for growth hormone deficiency, in adults, 601–602
 in children, 589–591
 for insulin-like growth factor deficiency, 625
 for thyroid disorders, congenital, 493, 496–497
 in premature newborns, 510
- Secretagogues, for growth hormone deficiency screening, in adults, 601–602
- Serial analysis of gene expression (SAGE), 484–485
- “Set point,” change of, in congenital thyroid disorders, 493
- Sex change, therapeutic choices for, molecular genetic studies in, 473
- Sex steroid priming, in provocative testing, for growth hormone deficiency, 591
- Sexual precocity. *See Precocious puberty.*
- Short bowel syndrome (SBS), in adults, causes of, 604
 growth hormone therapy for, 604–605
 animal data on, 603–604
- Short stature, in children, chronic kidney disease associated with, 591–593
 genetics of, 476–477
 hormone deficiencies associated with, 624, 627
 idiopathic, characteristics of, 598–599
 estrogen suppression for, 618
 growth hormone therapy for, 599
 pubertal growth maximizing strategies for, **613–624**
 aromatase inhibitors as, 613–619
 chemical structure of, 613–614
 doses and safety of, 618–619
 estradiol assay and, 618
 gonadotropin-independent precocity and, 617
 pharmacology of, 613–614
 physiologic studies of, 614–615
 potency of, 617–618
 studies in boys with growth disorders, 614–617
 GnRH analogs as, 613–614
 high-dose growth hormone as, 613–614
 summary overview of, 613, 621
 rickets vs., 575
 Venn diagram of, 624
- Short stature homeobox-containing gene (SHOX) gene deficiency, in children, growth hormone therapy for, 599
- Sibutramine, for obesity, 536–537
- Sick euthyroid syndrome, in premature newborns, 511–512
- Sim1 factor, obesity role of, 527–528
- Single-nucleotide polymorphisms (SNPs), bone growth and, 575
 obesity and, 530–531
- Sirtuins, bone growth regulation by, 573
- Small for gestational age (SGA), definition of, 598
 growth hormone therapy for, 598
- Social-ecological model, of obesity, 525–526, 531, 533

Somatomedin C, 625–626
 Spermatogenesis, estrogen role in, aromatase blockade and, 618–619
 Src homology protein tyrosine phosphatase-2 (SHP-2), in Noonan syndrome, 600
 STAT pathways, in chronic renal insufficiency, 593
 in insulin-like growth factor-1 deficiency, 624–626
 Stress response, in premature newborns, adrenal insufficiency and, 515
 Syndromic obesity, 531–532, 537

T

Temporary adrenal insufficiency of the premature (TAP), 515
 Testosterone, for boys with short stature, 614–617
 Testotoxicosis, precocious puberty related to, 617
 Thyroid disorders, congenital, **491–507**. See also *Congenital thyroid disorders*.
 alternating hypo-, eu-, and hyperthyroidism in neonatal period, 496, 501
 genetic counseling for, 501
 genetics of, 492–496
 hyperthyroidism, 501–504
 hypothyroidism, 496–501
 ontogenesis of, 491–492
 screening for, 493, 496–497
 genetics of, 477
 hyperthyroidism as. See *Hyperthyroidism*.
 hypothyroidism as. See *Hypothyroidism*.
 in sick and premature newborns, 509–512
 functional hormone patterns in, 510
 nonthyroidal illness as, 511–512
 overview of, 509–510
 primary hypothyroidism as, 512
 screening for, 510
 sick euthyroid syndrome as, 511–512
 transient hypothyroxinemia as, 510–511
 Thyroid function, in premature newborns, 510
 ontogenesis of, 491–492. See also *Thyroid disorders*.
 Thyroid gland, fetal, ontogenesis of, 491–492
 tumors of, gene encoding in, 473
 Thyroid hormone resistance, central, in congenital thyroid disorders, 492–493, 495
 Thyroid hormone transporter defect, 492, 495
 Thyroid-stimulating hormone (TSH), in premature newborns, 509–510
 disorders of, 510–512
 Thyrotoxicosis, neonatal, 501–504. See also *Neonatal hyperthyroidism*.
 Thyrotropin, in thyroid function ontogenesis, 492
 clinical manifestations of, 497–498
 scoring of with measurements, 498
 maturation and illness role, 493
 negative feedback mechanism changes and, 493, 495
 screening for, 493, 496–497
 Thyrotropin receptor stimulating–blocking antibodies (TRSAbs), congenital thyroid disorders
 and, 496, 501, 503–504
 Thyroxine (T4), for congenital hypothyroidism, 498, 500–501
 in premature newborns, 510

- disorders of, 510–512
- in thyroid function ontogenesis, 492
- maturation and illness role, 493
- negative feedback mechanism changes and, 493, 495
- screening for, 497
- neonatal hyperthyroidism treatment impact on, 502, 504
- Thyroxine-binding globulin (TBG), in premature newborns, 510
- Toddler Turner Study, 596
- Trace minerals, bone growth and, 575–576
- Triglycerides, in metabolic syndrome, 550–552
 - fatty liver and, 556–557
- Triiodothyronine (T3), in premature newborns, 510
 - disorders of, 511–512
- Tumor necrosis factor (TNF)- α , metabolic syndrome and, 551, 553–555
- Turner syndrome (TS), in children, features of, 594–595
 - growth hormone therapy for, 596
- Type 1 diabetes mellitus, bone growth and, 569
- Type 2 diabetes mellitus, genetics of, 554–555, 558
 - metabolic syndrome associated with, 551–552, 557
 - fatty liver and, 556
 - impaired glucose tolerance and, 554–555
- Tyrosine phosphatase, nonreceptor type 11 (PTPN11) gene, in Noonan syndrome, 600–601

U

- Urine ketones, in premature newborns, hypoglycemia and, 518

V

- Vacuolar protein sorting 34 (Vps34), bone growth and, 572
- VDR gene, bone growth and, 574–575
- Velocardiofacial syndrome, in premature newborns, hypocalcemia and, 513
- Venn diagram, of short stature, 624
- Vertical banded gastroplasty, for obesity, 539
- Very low birth weight (VLBW) infants, hyperglycemia in, 518
 - thyroid disorders in, 510
- Very low energy diets, for obesity, in children, 535
- Vitamin A, bone growth and, 575
- Vitamin B, bone growth and, 576
- Vitamin C, bone growth and, 576
- Vitamin D, bone growth and, 574–575
 - deficiency of, in premature newborns, hypocalcemia and, 513–514
- Vitamin E, bone growth and, 576

W

- Waist circumference, in metabolic syndrome, 550–552
- Web sites, on genetic information, 472
- Weight gain, in children. See *Obesity*.

Z

- Zinc, bone growth and, 575–576